Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single Arm, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MT027 in Patients with Pleural Malignant Tumors

NCT06726564 is registered in ClinicalTrials.gov with Suzhou Maximum Bio-tech Co., Ltd. as lead sponsor.

NCT NCT06726564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06726564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single Arm, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MT027 in Patients with Pleural Malignant Tumors
Lead sponsor
Suzhou Maximum Bio-tech Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 15, 2024
Completion date
February 28, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumor, malignant pleural effusion, pleura carcinoma, pleural malignant mesothelioma, pleural mesothelioma, pleural metastases